Testing effectiveness (Phase 2)Study completedNCT06331624
What this trial is testing
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF
Who this might be right for
Idiopathic Pulmonary FibrosisIPF
GRI Bio Operations, Inc. 35